TUBB4B
| Official symbol: | TUBB4B |
| Full name: | tubulin beta 4B class IVb |
| Location: | 9q34.3 |
| Also known as: | TUBB2C, Beta2 |
| Entrez ID: | 10383 |
| Ensembl ID: | ENSG00000188229 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.39 | | Gscore (Del): | 0.38 |
|
|
| Recurrently amplified in 2 cancer type(s) | | Recurrently deleted in 2 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 8.09 (Percentile rank: 33.36%) |
| PubTator score: | 147.43 (Percentile rank: 82.56%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
